The $3.4 Billion Lesson Pharma Faces in Shelved Drugs
Thousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
Start adopting wealth creation habits now to boost your financial success. These practical tips will guide you toward greater wealth.
19,833 articlesThousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
YieldMax’s Ultra Option Income Strategy ETF (ULTY) keeps paying weekly, but volatility is the fuel and risk. This rep...
A fresh cash bid for Two Harbors Investment Corp. sparks a renewed bidding war, putting pressure on UWM to top terms ...
A high-profile insider move has many ALAB investors wondering what comes next. This article breaks down the $60.5 mil...
U.S. policymakers confront a volatile oil backdrop and rising pump prices, weighing reserves, production, and demand ...
A Goldman Sachs strategist warns that leverage is rising across retail investors, hedge funds, and leveraged ETFs, po...
As March unfolds, the stock market today, march narrative centers on margins, capex trends, and AI-driven demand. Thi...
A local Omaha student believed a remote data-entry job would boost his resume, only to deposit a fraudulent check and...
In March 2026, the drug stock landscape blends steady demand with ongoing innovation. This article highlights three c...
Nigel Farage quit Parliament today as two investigations into gifts tied to crypto stakeholders unfold, triggering re...
Dell Technologies slid sharply on a broader AI rotation, yet fundamentals remained solid, prompting Jim Cramer to cal...
Eli Lilly's blockbuster first quarter puts the spotlight on a possible stock split as its high-priced shares approach...